Crystals of anti-human PD-1 monoclonal antibodies
US11014986B2 · kind B2 · utility
1Cited by
9References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 22, 2016 |
| Grant date | May 25, 2021 |
| Priority date | — |
| Expiry date | Feb 22, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Crystals of pembrolizumab and structurally similar anti-PD-1 monoclonal antibodies are provided, as well as methods of producing such crystals, and uses of compositions comprising such antibody crystals, e.g. in treatment of cancers. The present invention satisfies these needs and more by providing pembrolizumab crystals and a method producing pembrolizumab crystals. One embodiment of the method of the invention produces crystals suitable for X-ray diffraction, and the inventors herein used such crystals to solve the three-dimensional structure of pembrolizumab to 2.3 A resolution.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.